Are HOOKIPA Pharma Inc. (HOOK) stocks a prudent buy?

Currently, HOOKIPA Pharma Inc. [HOOK] is trading at $1.54, up 4.76%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HOOK shares have gain 12.41% over the last week, with a monthly amount drifted -13.48%, and not seem to be holding up well over a long-time horizon.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 4, August 2022, HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022. In a post published today on Yahoo Finance, HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it will release its second quarter 2022 financial results and Company update before the market open on Thursday, August 11, 2022.

From an analyst’s perspective:

HOOKIPA Pharma Inc. [NASDAQ: HOOK] stock has seen the most recent analyst activity on November 12, 2021, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $6 for it. Previously, Morgan Stanley started tracking the stock with Overweight rating on April 08, 2021, and set its price target to $19. On November 03, 2020, Truist initiated with a Buy rating and assigned a price target of $21 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $19 on October 26, 2020. H.C. Wainwright started tracking with a Buy rating for this stock on September 27, 2019, and assigned it a price target of $15. In a note dated May 13, 2019, RBC Capital Mkts initiated an Outperform rating and iterated a target price of $23 on this stock.

This stock has fluctuated between a low of $1.25 and a high of $7.73 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $6.75 within the next 12 months. HOOKIPA Pharma Inc. [NASDAQ: HOOK] shares were valued at $1.54 at the most recent close of the market. An investor can expect a potential return of 338.31% based on the average price forecast.

Analyzing the HOOK fundamentals

Recent quarter sales for HOOKIPA Pharma Inc. [NASDAQ:HOOK] were 1.45 billion which represents -73.60% decline. Gross Margin for this corporation currently stands at +74.85% with Operating Margin at -442.73%, Pretax Margin comes in at -410.15%, and Net Margin reading is -410.15%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4867 points at the first support level, and at 1.4333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5667, and for the 2nd resistance point, it is at 1.5933.

HOOKIPA Pharma Inc. [HOOK] reported earnings per share of -$0.4 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.24/share, meaning a difference of $-0.16 and a surprise factor of -66.70%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.65 per share as compared to estimates of -$0.58 per share, a difference of $-0.07 representing a surprise of -12.10%.

Ratios To Look Out For

To put it in perspective, the Current Ratio for HOOKIPA Pharma Inc. [NASDAQ:HOOK] is 5.50. Also, the Quick Ratio is 3.69, while the Cash Ratio stands at 2.40. Considering the valuation of this stock, the price to sales ratio is 4.15, the price to book ratio is 0.81.

Transactions by insiders

We now turn our attention to insider trading, which in the past 3 months has resulted in 0 insider buyings of 0 shares and 0 insider sellings of 0 shares. Recent insider trading involved Matushansky Igor, Chief Medical Officer, that happened on Dec 21 when 14949.0 shares were sold.